Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has demonstrated consistent weight loss results in clinical practice, with participants losing an average of 15 to 22 pounds over 68 weeks in landmark trials. Unlike traditional diet and exercise alone, semaglutide works by signaling the brain's appetite control centers to reduce hunger while also slowing how quickly food moves through your stomach. PlexusDx compounds pharmaceutical-grade semaglutide injections from licensed 503A pharmacies, delivering this proven treatment to all 50 states without insurance requirements.

How Semaglutide Triggers Weight Loss at the Cellular Level

Semaglutide binds to GLP-1 receptors located in the hypothalamus, a brain region that regulates hunger and energy expenditure. When these receptors activate, they send satiety signals that tell your body you feel full with smaller meal portions. The medication also slows gastric emptying—the rate at which your stomach releases food into the small intestine—which extends that feeling of fullness for hours after eating. This dual mechanism addresses both the psychological and physiological drivers of overeating, making calorie reduction feel less restrictive than traditional dieting.

Beyond appetite suppression, semaglutide improves insulin sensitivity and may increase resting metabolic rate in some patients. Research shows that GLP-1 activation enhances pancreatic function, helping regulate blood sugar more efficiently and reducing cravings for high-calorie, high-sugar foods. These metabolic adaptations compound over weeks and months, creating sustained weight loss momentum even if a patient's food intake eventually stabilizes.

Clinical Trial Evidence: Real Weight Loss Numbers

The SUSTAIN and STEP clinical trial programs tracked semaglutide's effectiveness across diverse patient populations over 68 weeks. Participants receiving the 2.4 mg weekly dose (the standard therapeutic dose for weight management) lost an average of 10.5 kg (23 pounds), representing approximately 15% of baseline body weight. In comparison, participants on placebo lost only 2.6 kg, meaning semaglutide-treated patients achieved roughly 8 times greater weight reduction. These results held across age groups, baseline weights, and ethnic backgrounds, suggesting broad clinical applicability.

Weight loss on semaglutide typically follows a predictable pattern: most patients see meaningful loss within 4 to 8 weeks as their appetite decreases, with the steepest declines occurring between weeks 8 and 20. Plateaus are common around week 24, but many patients experience secondary weight loss phases as their bodies adapt to the medication and metabolic improvements accumulate. Discontinuation studies show that weight tends to return gradually if semaglutide is stopped, confirming that the medication must be maintained to sustain benefits.

Why Genetic Variation Affects Your Personal Semaglutide Response

Not all patients respond identically to semaglutide, and genetic differences in GLP-1 receptor function explain much of this variation. The GLP1R rs6923761 variant, located within the gene encoding the GLP-1 receptor itself, influences how efficiently your cells bind and respond to the medication. Patients carrying certain alleles at this locus may require slightly different dose escalation schedules or experience stronger appetite suppression at lower doses. PlexusDx's Precision Peptide Genetic Test maps this and 48 other peptide-related variants across 14 metabolic pathways, revealing whether your genetic profile favors rapid response, moderate response, or may benefit from dose optimization.

Additional variants in the FTO gene (rs9939609) and MC4R gene (rs17782313) also influence baseline appetite regulation and energy expenditure, affecting how much additional benefit semaglutide provides on top of your genetic baseline. A patient genetically predisposed to lower appetite sensitivity may see dramatic effects, while someone with high genetic appetite drive might require more aggressive dosing or combination therapy. Testing for these variants before or during treatment allows PlexusDx providers to personalize your dose timing and concentration, ensuring you receive the most effective therapy for your unique biology.

Starting Semaglutide at PlexusDx: Dosing, Cost, and Access

PlexusDx offers compounded semaglutide injections starting at $149 per month through three flexible commitment tiers, with prices remaining flat regardless of your dose level—because your dose may need to go up, your price won't. All medications are manufactured by licensed 503A compounding pharmacies and shipped to all 50 states with no insurance requirement, no membership fees, and HSA or FSA eligibility. Most patients begin with a 0.25 mg weekly dose and increase by 0.25 mg every 4 weeks until reaching an effective dose (typically 1.0 to 2.4 mg weekly), but PlexusDx can customize your starting point and escalation schedule based on your genetic profile and clinical history.

After your first month of treatment, you can add the Precision Peptide Genetic Test for $99 to unlock insights into your GLP1R, GIPR, FTO, and MC4R variants, plus 150 additional genetic markers across appetite, energy, and metabolic pathways. This test guides dose optimization and helps predict whether combination therapy (such as PlexusDx's GLP-Squared Injection combining semaglutide and tirzepatide) might deliver faster or greater results. Licensed providers review your genetic report and adjust your treatment plan accordingly, ensuring your therapy evolves with your body's response.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight can I realistically expect to lose on semaglutide?

Most patients lose 10 to 22 pounds over 68 weeks of treatment, or roughly 15% of baseline body weight. Your personal results depend on genetics, starting weight, lifestyle adherence, and dose level. PlexusDx's Precision Peptide Genetic Test can help predict your likely response range based on your GLP1R and appetite-control variants.

How quickly does semaglutide start working for weight loss?

Many patients notice reduced hunger and smaller portion sizes within 1 to 2 weeks of starting semaglutide, with measurable weight loss visible on the scale by week 4. The most rapid loss typically occurs between weeks 8 and 20 as your body adapts to the medication's appetite-suppressing effects. Weight loss then usually slows but continues at a steady pace through month 3 and beyond.

What does semaglutide cost at PlexusDx, and is it covered by insurance?

PlexusDx's compounded semaglutide injection starts at $149 per month across three commitment tiers, with your price staying flat no matter your dose. The service does not require insurance, membership fees, or special enrollment—and HSA and FSA cards are accepted for all patients in all 50 states.

Are there side effects I should expect when starting semaglutide?

Common side effects include mild nausea, constipation, and stomach discomfort, especially during the first 1 to 2 weeks as your body adjusts. These typically fade as your body accommodates the medication; starting at a low dose and increasing gradually (as PlexusDx protocols recommend) minimizes adverse effects. Serious side effects are rare but can include pancreatitis; alert your provider immediately if you experience severe abdominal pain.

Can genetic testing predict how well I'll respond to semaglutide?

Yes. PlexusDx's Precision Peptide Genetic Test analyzes your GLP1R rs6923761 variant (which directly affects GLP-1 receptor sensitivity), plus FTO and MC4R variants influencing baseline appetite and energy expenditure. These genetic insights, combined with 150+ other metabolic markers, help your provider estimate your likely response strength and optimize your starting dose and escalation timeline for faster, stronger results.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves